New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis

References

• HopeWWInvasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosisMed Mycol200947Suppl 1S291S29819306226
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJEpidemiology of invasive mycoses in North AmericaCrit Rev Microbiol20103615320088682
   PubMed Web of Science ®Google Scholar
• LeJSchillerDSAerosolized delivery of antifungal agentsCurr Fungal Infect Rep201049610220502511
   PubMedGoogle Scholar
• LabirisNRDolovichMBPulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBr J Clin Pharmacol20035660061214616419
   PubMed Web of Science ®Google Scholar
• DuretCWauthozNSebtiTVanderbistFAmighiKSolid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion propertiesInt J Pharm201242810311322414388
   PubMed Web of Science ®Google Scholar
• MobleyCHochhausGMethods used to assess pulmonary deposition and absorption of drugsDrug Discov Today2001636737511267923
   PubMed Web of Science ®Google Scholar
• MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the futureAdv Drug Deliv Rev20014731911251242
   PubMed Web of Science ®Google Scholar
• RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov2004378579615340388
   PubMed Web of Science ®Google Scholar
• SungJCPulliamBLEdwardsDANanoparticles for drug delivery to the lungsTrends Biotechnol20072556357017997181
   PubMed Web of Science ®Google Scholar
• ShamJOZhangYFinlayWHRoaWHLobenbergRFormulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lungInt J Pharm200426945746714706257
   PubMed Web of Science ®Google Scholar
• YangWPetersJIWilliamsRO3rdInhaled nanoparticles – a current reviewInt J Pharm200835623924718358652
   PubMed Web of Science ®Google Scholar
• WeersJGDispersible powders for inhalation applicationsInnov Pharm Technol20001111116
   Google Scholar
• El GendyNBerklandCCombination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomerationPharm Res2009261752176319415471
   PubMed Web of Science ®Google Scholar
• El GendyNGormanEMMunsonEJBerklandCBudesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolutionJ Pharm Sci2009982731274619130469
   PubMed Web of Science ®Google Scholar
• PilcerGVanderbistFAmighiKPreparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary deliveryInt J Pharm200936516216918782609
   PubMed Web of Science ®Google Scholar
• SalemHAbdelrahimMEidKASharafMNanosized rods agglomerates as a new approach for formulation of a dry powder inhalerInt J Nanomedicine2011631132021383856
   PubMed Web of Science ®Google Scholar
• DaviskasEAndersonSDJaquesACharltonBInhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosisChest201013786186819880909
   PubMed Web of Science ®Google Scholar
• HindsWCAerosol Technology: Properties, Behavior, and Measurement of Airborne Particles2nd edNew YorkWiley19994247
   Google Scholar
• SonYJMcConvilleJTDevelopment of a standardized dissolution test method for inhaled pharmaceutical formulationsInt J Pharm2009382152219665533
   PubMed Web of Science ®Google Scholar
• PhamSWiedmannTSNote: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactantJ Pharm Sci2001909810411064383
   PubMed Web of Science ®Google Scholar
• Van EerdenbrughBVan denMGAugustijnsPTop-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid productsInt J Pharm2008364647518721869
   PubMed Web of Science ®Google Scholar
• HecqJDeleersMFanaraDVranckxHAmighiKPreparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipineInt J Pharm200529916717715996838
   PubMed Web of Science ®Google Scholar
• KeckCMMullerRHDrug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEur J Pharm Biopharm20066231616129588
   PubMed Web of Science ®Google Scholar
• Van EerdenbrughBVan den MooterGAugustijnsPTop-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid productsInt J Pharm2008364647518721869
   PubMed Web of Science ®Google Scholar
• PilcerGAmighiKFormulation strategy and use of excipients in pulmonary drug deliveryInt J Pharm201039211920223286
   PubMed Web of Science ®Google Scholar
• WangBZhangWZhengWMujumdarASHuangLProgress in drying technology for nanomaterialsDrying Technol200423118
   Web of Science ®Google Scholar
• Van EerdenbrughBFroyenLVan HumbeeckJMartensJAAugustijnsPVan den MooterGDrying of crystalline drug nanosuspensions – the importance of surface hydrophobicity on dissolution behavior upon redispersionEur J Pharm Sci20083512713518644441
   PubMed Web of Science ®Google Scholar
• ChaubalMVPopescuCConversion of nanosuspensions into dry powders by spray drying: a case studyPharm Res2008252302230818509597
   PubMed Web of Science ®Google Scholar
• ChanHKGondaIDevelopment of a systematic theory of suspension inhalation aerosols. 2. Aggregates of monodisperse particles nebulized in polydisperse dropletsInt J Pharm198841147157
   Web of Science ®Google Scholar
• BinksBPParticles as surfactant – similarities and differencesCurr Opin Colloid Interface Sci200272141
   Web of Science ®Google Scholar
• MajumderMRendallCEukelAWangJNatnaelBehabtuPintCLiuTOrbaekAMirriFNamJ,BarronAHaugeRSchmidtHPasqualiMOvercoming the “Coffee-Stain” Effect by Compositional Marangoni-Flow- Assisted Drop-DryingJ Phys chem201211665366542
   PubMed Web of Science ®Google Scholar
• TsapisNBennettDJacksonBWeitzDEdwardsDATrojan particles: large porous carriers of nanoparticles for drug deliveryProc Natl Acad Sci U S A200299120011200512200546
   PubMed Web of Science ®Google Scholar
• StroockADDertingerSKAjdariAMezicIStoneHAWhitesidesGMChaotic mixer for microchannelsScience200229564765111809963
   PubMed Web of Science ®Google Scholar
• HaoJLiSKMechanistic study of electroosmotic transport across hydrated nail plates: effects of pH and ionic strengthJ Pharm Sci2008975186519718386836
   PubMed Web of Science ®Google Scholar
• DuretCWauthozNSebtiTVanderbistFAmighiKNew respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosisPharm Res2012291028455922644590
   PubMed Web of Science ®Google Scholar
• MorrisGKokkiMHAndersonKRichardsonMDSampling of Aspergillus spores in airJ Hosp Infect200044819210662557
   PubMed Web of Science ®Google Scholar
• EduardWFungal spores: a critical review of the toxicological and epidemiological evidence as a basis for occupational exposure limit settingCrit Rev Toxicol20093979986419863384
   PubMed Web of Science ®Google Scholar
• PasqualottoACDifferences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavusMed Mycol200947Suppl 1S261S27018654921
   PubMed Web of Science ®Google Scholar
• WeilerCEgenMTrunkMLangguthPForce control and powder dispersibility of spray dried particles for inhalationJ Pharm Sci20109930331619533606
   PubMed Web of Science ®Google Scholar
• SoubaniAOChandrasekarPHThe clinical spectrum of pulmonary aspergillosisChest20021211988199912065367
   PubMed Web of Science ®Google Scholar
• ChewNYTangPChanHKRaperJAHow much particle surface corrugation is sufficient to improve aerosol performance of powders?Pharm Res20052214815215771241
   PubMed Web of Science ®Google Scholar
• ByronPRPeartJStaniforthJNAerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalersPharm Res1997146987059210184
   PubMed Web of Science ®Google Scholar
• YangWJohnstonKPWilliamsRO3rdComparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in ratsEur J Pharm Biopharm201075334120102737
   PubMed Web of Science ®Google Scholar
• DenningDWHopeWWTherapy for fungal diseases: opportunities and prioritiesTrends Microbiol20101819520420207544
   PubMed Web of Science ®Google Scholar
• ZhangJWuLChanHKWatanabeWFormation, characterization, and fate of inhaled drug nanoparticlesAdv Drug Deliv Rev20116344145521118707
   PubMed Web of Science ®Google Scholar
• PetersKKrussBBeckerRMüllerRHPharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution United States patent US005858410A1121999
   Google Scholar
• MüllerRHPetersKNanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction techniqueInt J Pharm1998160229237
   Web of Science ®Google Scholar
• LeeRWShawJMMcShaneJWoodRWParticle size reductionLiuRWater-Insoluble Drug FormulationDenverInterpharm Press2000455492
   Google Scholar
• KayaertPAnneMVan denMGBead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beadsJ Pharm Pharmacol2011631446145321988425
   PubMed Web of Science ®Google Scholar